Title:
PHARMACEUTICALLY ACCEPTABLE SALT OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST, AND CRYSTALLINE FORM THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/220601
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutically acceptable salt of a sphingosine-1-phosphate receptor agonist and a crystalline form thereof, and more specifically, to a potassium salt or methanesulfonate of 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-3,4-dihydro-naphthalen-2-ylmethyl]-piperidine-4-carboxylic acid of formula 1, and a crystalline form thereof.
Inventors:
CHUN SEUL AH (KR)
KIM SUNG WOOK (KR)
KIM JI YOON (KR)
KIM SUNG WON (KR)
PARK KI SOOK (KR)
KIM SUNG WOOK (KR)
KIM JI YOON (KR)
KIM SUNG WON (KR)
PARK KI SOOK (KR)
Application Number:
PCT/KR2022/005378
Publication Date:
October 20, 2022
Filing Date:
April 13, 2022
Export Citation:
Assignee:
LG CHEMICAL LTD (KR)
International Classes:
C07D401/12; A61K31/454; A61P25/00; A61P37/00
Domestic Patent References:
| WO2008064320A2 | 2008-05-29 | |||
| WO2014129796A1 | 2014-08-28 | |||
| WO2014129796A1 | 2014-08-28 |
Foreign References:
| KR20140104376A | 2014-08-28 | |||
| EP1826197A1 | 2007-08-29 | |||
| US10166250B2 | 2019-01-01 | |||
| US20080200535A1 | 2008-08-21 |
Attorney, Agent or Firm:
HANSUNG INTELLECTUAL PROPERTY (KR)
Download PDF: